Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of
vision and blindness among working age adults. An ideal adjunctive agent for treating DR
hence should be polymorphic and possess antiangiogenic, neuroprotective, anti-inflammatory,
anti-oxidant as well as anti-ischaemic properties.Natureceuticals Sdn Bhd assessed the
efficacy of core ingredient of Nuvastatic™, Lanctos 75™ for the treatment and management of
the diabetic retinopathic condition.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Natureceuticals Sdn Bhd
Collaborators:
Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia Ministry of Agriculture, Malaysia Quest International University, Malaysia. Universiti Sains Malaysia